Johnson & Johnson Fiscal Q3 Adjusted Earnings Fall, Sales Increase; Fiscal 2026 Guidance Lifted

06:47 AM EDT, 10/13/2026 (MT Newswires) -- Johnson & Johnson (JNJ) reported fiscal Q3 adjusted earnings Tuesday of $2.59 per diluted share, down from $2.80 a year earlier. Analysts polled by FactSet expected $2.52. Reported sales for the fiscal quarter ended Sept. 27 were $25.40 billion, up from $23.99 billion a year earlier. Analysts polled by FactSet expected $25.38 billion. For fiscal 2026, the pharmaceuticals major lifted its projected adjusted EPS guidance to between $11.05 and $11.15 from a previous range of $10.96 to $11.11. Analysts polled by FactSet expect $11.19 The company lifted its reported sales for fiscal 2026 to be between $101.0 billion and $101.4 billion from a previous range of $100.8 billion to $101.4 billion. Analysts polled by FactSet expect $101.33 billion. Shares of the company were down 1.7% in Tuesday premarket activity.